#clinicalAI Tag

08 Jul

Posted at 12:01h in AI and HealthCare, Technology

The planning assumptions that worked in 2022 are quietly failing. In 2022, healthcare CIOs were building business cases for AI pilots. In 2026, they're being asked why the pilots haven't become products. In 2022, cybersecurity was a compliance topic. In 2026, the Change Healthcare ransomware attack — which affected 192.7 million Americans, roughly two-thirds of the US population — turned it into a board-level operational risk that no CTO can defer. In 2022, interoperability was a regulatory aspiration. In 2026, it's a technical prerequisite for any system that touches patient data.

Clinical companies entering the second half of the decade are navigating a different kind of pressure. Budgets are tighter: 41% of health system executives anticipate reduced capital investment over the next two years, according to a March 2026 survey by Sage Growth Partners. The window for exploratory technology spending is narrowing. At the same time, the expectations for what technology needs to deliver — in clinical efficiency, data security, and measurable patient outcomes — have grown sharply. Every line item now needs a business case, and every business case needs to hold up against harder questions than it would have two or three years ago.

Healthcare Technology Priorities

24 Jun

Posted at 14:23h in Medical Records, Technology
The phrase "custom AI solutions for healthcare" has been stretched to cover everything from a chatbot that answers FAQ questions to a clinician-reviewed diagnostic model trained on 10 million labeled images. That spectrum matters for vendor selection, because the right company for a conversational patient engagement tool is categorically different from the right company for a radiology AI system. This guide focuses on companies building meaningful custom AI — systems that process clinical data, generate outputs that influence care or operations, and operate under regulatory frameworks that hold their developers accountable for what those outputs say. Seven companies are profiled, each evaluated with a Strengths / Limitations / Verdict framework that gives you a direct, unhedged read on what each company does well and where it falls short.